Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
6.07
+0.01 (0.17%)
At close: Jun 24, 2025, 4:00 PM
6.12
+0.05 (0.82%)
Pre-market: Jun 25, 2025, 8:24 AM EDT
Prothena Corporation Revenue
Prothena Corporation had revenue of $2.83M in the quarter ending March 31, 2025, with 5,556.00% growth. This brings the company's revenue in the last twelve months to $137.94M, up 54.55% year-over-year. In the year 2024, Prothena Corporation had annual revenue of $135.16M with 47.92% growth.
Revenue (ttm)
$137.94M
Revenue Growth
+54.55%
P/S Ratio
2.37
Revenue / Employee
$846,227
Employees
163
Market Cap
326.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PRTA News
- 6 days ago - Prothena Announces Corporate Restructuring - Business Wire
- 9 days ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 4 weeks ago - Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
- 4 weeks ago - Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint - Business Wire
- 6 weeks ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga
- 6 weeks ago - Prothena Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 7 weeks ago - Prothena to Report First Quarter 2025 Financial Results on May 8 - Business Wire
- 4 months ago - Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript - Seeking Alpha